Latest News
- November 18, 2025ANDA application for Bimatoprost ophthalmic solution received Marketing Authorization from the USFDA!
- November 12, 2025ANDA application for Risperidone extended-release injectable suspension has received Marketing Authorization from the USFDA!
- October 30, 2025Accelerating Clinical Research!
- September 12, 2025Join CBCC at CPHI Frankfurt 2025
- August 08, 2025International Publication of Phase II clinical Trial
July 03, 2025
Successful completion of an unannounced USFDA inspection
Regulatory Win
We are pleased to announce the successful completion of an unannounced USFDA inspection with ZERO 483 observations
Therapeutic Area: Ophthalmology
Site Location: Los Angeles, US
Inspection Month: June 2025
CBCC Global Research: Benchmarked to Global Standards of Excellence!
Manoj Vyas Dr. Sandeep Singh Jaimeen Vanparia Sanjeev Ganatra Nikhil Gandhi Harakh Shah, PMP® Tapan Shah Kinnari Gandhi RQAP-GCP Dr. Praveen Choudhary Nikunj Patel Ankit Parikh Ajit Upadhyaya Ankit Pandav Devang Pandya Jay Vyas Udayan Vyas
Zero483 RegulatoryCompliance Ophthalmology QualityAssurance LifeSciences InspectionReady